Clinical Trials Browser

Phase 2 × Withdrawn × Breast × Clear all

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06868238 2026-02-18

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

Phase 2 Withdrawn

Carcinoma, Intraductal, Noninfiltrating, Lymphedema

NCT06613516 2025-12-24

CaptAin

Phase 2 Withdrawn

Breast Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT06084689 2025-09-02

EMPIRE

Phase 2 Withdrawn

BreastGastrointestinalSarcomaThoracic

Tertiary Lymphoid Structures, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Sarcoma, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04756765 2025-08-17

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT03554109 2025-02-21

TNBC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05488444 2024-10-22

A Feasibility and Acceptability Pilot Study Evaluating a Patient-Specific Targeted Intervention Using Patient Navigators or Routine Clinical Care

Phase 2 Withdrawn

Breast Neoplasms

NCT06105008 2024-08-23

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT05212701 2024-04-30

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Fatigue

NCT05967286 2024-03-20

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Phase 2 Withdrawn

Anatomic Stage III Breast Cancer AJCC v8

NCT03841747 2024-03-12

PELICAN

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

Phase 2 Withdrawn

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

NCT05689359 2024-03-08

Evaluation of Hydroxychloroquine to Prevent CIPN

Phase 2 Withdrawn

Breast Neoplasms, Peripheral Nervous System Diseases

NCT04199520 2024-03-04

Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients

Phase 2 Withdrawn

Breast Neoplasms

NCT05703555 2024-02-28

INTRUSION

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Stomach Neoplasms

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05315687 2024-01-19

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Phase 2 Withdrawn

Breast Neoplasms

NCT04265274 2023-10-06

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Phase 2 Withdrawn

Breast Neoplasms

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT04901299 2023-08-01

HER2-Signal

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT02067416 2023-02-02

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT03982173 2023-01-26

MATILDA

Phase 2 Withdrawn

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03666819 2023-01-06

Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

Phase 2 Withdrawn

Breast Carcinoma In Situ, Dyspareunia

NCT04538833 2022-11-23

GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

Phase 2 Withdrawn

Breast Neoplasms

NCT05041972 2022-09-13

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Phase 2 Withdrawn

BreastGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05227131 2022-07-11

MARGARET

Phase 2 Withdrawn

Breast Neoplasms

NCT02850419 2022-04-07

EURO-DIGNITY

Phase 2 Withdrawn

Breast Neoplasms

NCT04856475 2022-03-02

NeraBrain

Phase 2 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT05008510 2022-02-08

VERU-111

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT02161679 2021-08-19

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03863301 2021-02-26

ABLATIVE-2

Phase 2 Withdrawn

Breast Neoplasms

NCT03524261 2020-10-19

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT04220476 2020-09-21

CIMER

Phase 2 Withdrawn

Breast Neoplasms

NCT01818999 2020-08-20

Ixabepilone and SBRT For Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT03393117 2020-07-22

Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction

Phase 2 Withdrawn

Breast Neoplasms

NCT04149444 2020-06-11

TACTIC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT03637868 2020-05-06

ERIBRAIN

Phase 2 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT01924351 2020-03-18

HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)

Phase 2 Withdrawn

Breast Cancer With Brain Metastasis

NCT03323424 2020-01-30

IRAM

Phase 2 Withdrawn

BreastGastrointestinalHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT03532087 2020-01-18

PERIDENO

Phase 2 Withdrawn

Breast Neoplasms

NCT02853071 2019-11-18

BEST

Phase 2 Withdrawn

Breast Neoplasms

NCT03185871 2019-11-15

Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses

Phase 2 Withdrawn

Breast Neoplasms

NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

Phase 2 Withdrawn

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

NCT03794596 2019-07-22

IMpALA

Phase 2 Withdrawn

Breast Neoplasms

NCT00960544 2019-06-14

Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Phase 2 Withdrawn

Breast Neoplasms

NCT03644589 2019-04-26

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03203616 2018-11-29

KIARA

Phase 2 Withdrawn

Metastatic HER2-positive Breast Cancer With Brain Metastasis